An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Fig. 1. Longitudinal whole-body dual-energy x-ray absorptiometry (DEXA)–derived measures of areal BMD (aBMD) (A and C) and BMC (B and D), collected in female (A and B) and male (C and D) mice. From: Sclerostin Inhibition Reverses Skeletal Fragility in an Lrp5-Deficient Mouse Model of OPPG Syndrome.
CitationFull text
Fig. 3. Monotonic three-point bending tests to failure of femora from 16.5-week-old male and female wild-type, Lrp5−/−, Sost−/−, and Lrp5−/−;Sost−/− mice. From: Sclerostin Inhibition Reverses Skeletal Fragility in an Lrp5-Deficient Mouse Model of OPPG Syndrome.
Fig. 4. Midshaft femur fluorochrome-derived BFRs on the periosteal surface collected from 16.5-week-old male Lrp5−/−, Sost−/−, and Lrp5−/−;Sost−/− mice. From: Sclerostin Inhibition Reverses Skeletal Fragility in an Lrp5-Deficient Mouse Model of OPPG Syndrome.
Fig. 6. Midshaft femur fluorochrome-derived BFRs on the periosteal surface of 20-week-old female Lrp5+/+ and Lrp5−/− mice that had been treated for 3 weeks with vehicle or a sclerostin antibody (Scl-AbIII). From: Sclerostin Inhibition Reverses Skeletal Fragility in an Lrp5-Deficient Mouse Model of OPPG Syndrome.
Fig. 2. mCT-derived measurements of the distal femur trabecular bone and midshaft femur cortical bone in wild-type, Lrp5−/−, Sost−/−, and Lrp5−/− Sost−/− mice, collected from male and female mice at 16.5 weeks of age. From: Sclerostin Inhibition Reverses Skeletal Fragility in an Lrp5-Deficient Mouse Model of OPPG Syndrome.
Fig. 5. DEXA- and mCT-derived measurements of bone mass, density, and architecture in female Lrp5+/+ and Lrp5−/− mice that had been treated for 3 weeks with vehicle or sclerostin antibody (Scl-AbIII). From: Sclerostin Inhibition Reverses Skeletal Fragility in an Lrp5-Deficient Mouse Model of OPPG Syndrome.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on